Selecta Biosciences, Inc. is developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. 

Selecta was founded based on the synergistic convergence of nanotechnology, targeted delivery and immunobiology by three pioneers in the field:  Dr. Robert Langer of MIT, Dr. Omid Farokhzad and Dr. Ulrich von Andrian of Harvard Medical School.

Contact Info

480 Arsenal Street, Building One, Watertown, MA, 02472
Tel: 617-723-1400

Polaris Lead

Amir Nashat

Social Media